Oracle, PwC Consulting and Pharsight form drug development initiative

According to the partnering companies, the new infrastructure is intended to: enable better trial and program design; better visibility to assess trial results; and more efficient compilation, control

By Editor on Dec 10, 2001

According to the partnering companies, the new infrastructure is intended to: enable better trial and program design; better visibility to assess trial results; and more efficient compilation, control and submission of regulatory data. In addition, the new system will be designed to provide improvements in productivity by providing all users with an integrated set of tools running against a unified database, in a controlled, validated, global environment.

Furthermore the system will incorporate technologies from Oracle and Pharsight, designed to optimize program and trial design, manage trial execution and streamline analysis and reporting of trial results. The system will enable customers and third-party suppliers to include their own technical solutions through the use of open interfaces.

"Today it costs an in excess of $600 million to bring a new drug to market," said Sohaib Abbasi, Senior Vice President of Oracle's Tools Division. "The primary end product of that investment is data, yet all too often the data is fragmented across multiple systems and is not easily available to the people who need it to make decisions rapidly and correctly. By unifying the data and providing simple, powerful tools that allow people to find and analyze the data they need when they need it, we expect to significantly improve the productivity of the drug development process."

"While a great deal of effort is currently being put into streamlining the collection of trial data, pharmaceutical companies lack the necessary tools to fully harness these data, and, hence, massively reduce the number, size and complexity of clinical trials," said Simon Hughes, Partner in PwC Consulting's Global Pharmaceutical practice. "The collaborative initiative announced today, between PwC Consulting, Oracle and Pharsight, draws together the technology and process skills needed to help bring about this transformation of the drug development process."

"Pharsight's mission has been to use science-based methodologies and innovative technologies to help pharmaceutical companies transform their development process to yield significantly better results," said Dan Weiner, Pharsight's Senior Vice President of Technology Deployment. "This collaboration will accelerate our efforts and provide pharmaceutical companies with a platform to dramatically improve the quality and timeliness of key decisions in drug development."

If you would like to find out more about the data and knowledge management systems available to you go to eyeforpharma.com/km. This is an event directly focused on reducing time to market by increase the information flow within a company. To get involved in this event please email sebastien@eyeforpharma.com